Reykjavik (IFN) New York-listed, Icelandic biotechnology company deCODE genetics has named Dr. Peter Goodfellow to its board of directors, effective immediately, the company said on Wednesday.
Dr. Goodfellow was until recently senior vice president for discovery research at GlaxoSmithKline, a position he held for the past six years.
Prior to this post, he held senior positions at SmithKline Beecham, the Balfour chair in genetics at Cambridge University and research positions at the Imperial Cancer Research Fund. Dr. Goodfellow received his doctorate from Oxford University and held a postdoctoral fellowship at Stanford University.
?Throughout his career Peter has worked to bring together genetics research and drug development. This focus makes him ideally suited to work with deCODE as we turn our gene discoveries into developmental compounds for common diseases. I believe his experience will be of great value to helping us to advance our product development work and I am very pleased to welcome him to deCODE," said Kari Stefansson, chief executive of deCODE.
Icelandic Financial News (IFN) is available on Factiva, a joint venture between Reuters and Dow Jones Newswires, FT.COM, LexisNexis, Comtex, Gale and Thomson via the Nordic Business Report.
Viðskiptablaðið er 25 ára og af því tilefni býðst nýjum áskrifendum að kaupa áskrift á 50% afslætti.
Afmælisverðið er aðeins 2.500 krónur.
Tilboðið er fyrir nýja áskrifendur. Núverandi áskrifendur geta bætt við sig áskrift á þessu verði. Gildir í 4 mánuði. Áskrifendur fá Viðskiptablaðið, Frjálsa verslun og Fiskifréttir sent ásamt vefaðgangi að vb.is og fiskifrettir.is